From: Clear cell carcinoma of the ovary: Is there a role of histology-specific treatment?
regimen | author | year | response/ Number of patients, response rate |
---|---|---|---|
Conventional Platinum-based | Goff [28] | 1996 | 1/6, 17% |
Sugiyama [29] | 2000 | 3/27, 11% | |
Ho [30] | 2004 | 4/15, 27% | |
Takano [9] | 2006 | 5/30, 17% | |
Taxane-Platinum | Enomoto [31] | 2003 | 2/9, 22% |
Ho [30] | 2004 | 9/16, 56% | |
Utsunomiya [32] | 2006 | 8/15, 53% | |
Takano [9] | 2006 | 9/28, 32% | |
Irinotecan-cisplatin | Takano [9] | 2006 | 3/10, 30% |